Susi Roger E. sold $691K of IRMD (indirect holdings)
Susi Roger E. (CEO, President, Chairman) sold 7,500 indirectly-held shares of IRADIMED CORP (IRMD) at an average of $92.14 ($91.81–$92.93, $0.69M total) across 4 trades over 2026-05-26 to 2026-05-27 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed fact is the timing, size, and price range of the insider’s indirect open-market sale, but it does not include new operational, financial, or regulatory developments.
Market read
This provides incremental transparency on insider activity, but it is unlikely to drive a major repricing without corroborating fundamental news.
What to watch
Because the filing confirms a pre-arranged 10b5-1 plan, the sale may be mechanically scheduled rather than information-driven; the article provides no accompanying fundamental update.
Background
The article is an SEC Form 4 insider transaction disclosure for IRMD, listing an officer/director/10% owner sale executed under a Rule 10b5-1 plan.
Ticker impact
IRMD CEO/Chairman Susi Roger sold $691K of IRMD shares via a 10b5-1 plan across 4 trades at about $91.81 to $92.93.
Likely minimal, though it can add short-term overhang if traders interpret it as supply.
Form 4 shows an open-market sale and explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No sector-wide implications; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Traders may still treat insider selling as a sentiment negative, especially if the stock is thinly traded or if other insiders are also selling.
Key entities
- issuerIRADIMED CORP
Company whose shares were sold by an insider under a 10b5-1 plan.
- insiderSusi Roger E.
CEO, President, Chairman; reported indirect holdings sale totaling $691,043.76.
